Investigation of post-treatment after immune checkpoint inhibitor treatment for advanced or recurrent non-small cell lung cancer

Investigation of post-treatment after immune checkpoint inhibitor treatment for advanced or recurrent non-small cell lung cancer - Investigation of post-treatment after immune checkpoint inhibitor treatment for advanced or recurrent non-small cell lung cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000033594

Enrollment

Registered

2018-08-01

Start date

2016-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Advanced or recurrent non-small cell lung cancer in which an immune check point inhibitor was used at our center

Exclusion criteria

Exclusion criteria: Patient, or family refuses to participate in the study

Design outcomes

Primary

Measure	Time frame
Response rate	—

Secondary

Measure	Time frame
Progression-free survival Overall survival Side effect Types of immunity checkpoint inhibitors Types of anti-cancer drugs	—

Countries

Japan

Contacts

Public ContactMari Tone

Japanese Red Cross Medical Center Respiratory Medicine

m.tone.0829@gmail.com03-3400-1311

Outcome results